Search results for "Mucositis"

showing 10 items of 103 documents

Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT).

2010

Aims: To establish whether or not the state of patient oral health can influence the occurrence and/or severity of oral mucositis during hematopoietic progenitor cell transplantation (HPCT). Materials and Methods: The study included 72 patients awaiting HPCT. Prior to transplantation, clinical exploration and radiology were carried out and oral photographs were taken. This evaluated the extent of caries present, the number of missing teeth and the number of dental fillings in each patient; CAO (Caries and Obturations Index) DMFS (Decayed, Missing, and Filled Surfaces) and Restoration Indices were calculated. Gingival pathology was also examined by means of the Ainamo and Bay Gingival Bleedi…

AdultMaleAdolescentmedicine.medical_treatmentDentistryOral HealthHematopoietic stem cell transplantationOral healthOral hygieneSeverity of Illness IndexYoung AdultSeverity of illnessmedicineMucositisHumansYoung adultChildGeneral DentistryStomatitisAgedStomatitisbusiness.industryHematopoietic Stem Cell TransplantationMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Transplantationstomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I–II study

2003

Our objective was to identify a new active three-drug combination regimen consisting of paclitaxel (PTX), epirubicin (EPI) and cisplatin as first-line line chemotherapy for advanced ovarian carcinoma. A phase I study was carried out to evaluate the dose-limiting toxicity (DLT) and the maximally tolerated dose (MTD) of PXT and EPI in combination with a fixed dose of cisplatin every 4 weeks. Side-effects were recorded according to the NCI Common Toxicity Criteria. Patients were treated in cohorts of three with fixed-dose cisplatin 80 mg/m 2 and EPI 80 → 100 mg/ m 2 and PXT 100 → 160 mg/m 2 until DLT was reached. Once MTD was identified, a single-step phase II study was therefore carried out t…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPaclitaxelmedicine.medical_treatmentUrologyPhases of clinical researchAntineoplastic AgentsPharmacologyAntineoplastic Combined Chemotherapy ProtocolsMucositisHumansMedicinePharmacology (medical)AgedEpirubicinNeoplasm StagingOvarian NeoplasmsPharmacologyCisplatinChemotherapyAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryCarcinomaMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisRegimenOncologyToxicityAntiemeticsFemaleCisplatinbusinessFebrile neutropeniamedicine.drugEpirubicinAnti-Cancer Drugs
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Supportive periodontal therapy and periodontal biotype as prognostic factors in implants placed in patients with a history of periodontitis

2013

Objectives: To evaluate bone loss around implants placed in patients with a history of treated chronic periodontitis and who did or did not attend supportive periodontal therapy, after one year in function. Furthermore, the influence of periodontal biotype and level of plaque was also evaluated. Material and Methods: Forty-nine patients participated voluntarily in the study. All subjects had a history of chronic periodontitis, which had been previously treated. After the active treatment, 27 patients attended supportive periodontal therapy (SPT) and the rest did not (No SPT). The O’Leary plaque index and periodontal biotype were recorded for each subject and 246 Astra Tech® OsseospeedTM imp…

AdultMaleDentistryOdontologíamedicineMucositisHumansPeriodontologyRisk factorGeneral DentistrySurvival rateAgedPeriodontitisOrthodonticsbusiness.industryDental prosthesisDental Plaque IndexMiddle Agedmedicine.diseasePrognosis:CIENCIAS MÉDICAS [UNESCO]Chronic periodontitisCiencias de la saludDental Plaque IndexOtorhinolaryngologyChronic PeriodontitisUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemaleImplantDental Prosthesis Implant-Supportedbusiness
researchProduct

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter p…

2010

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (2…

AdultMaleMucositisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAdrenocortical carcinomaSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhases of clinical researchDeoxycytidineGastroenterologyDrug Administration ScheduleCapecitabineEndocrinologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansMitotaneCapecitabineAgedChemotherapybusiness.industryLeukopeniaMiddle Agedmedicine.diseaseThrombocytopeniaGemcitabineAdrenal Cortex NeoplasmsGemcitabineRegimenTreatment OutcomeOncologyFluorouracilDisease ProgressionFemaleFluorouracilbusinessmedicine.drug
researchProduct

Streptococcal bacteraemia in patients submitted to hematopoietic stem cell transplantation: the role of tooth brushing and use of chlorhexidine.

2009

A retrospective evaluation of 73 consecutive recipients of hematopoietic stem cell transplantation (HSCT) was conducted to investigated the role of oral care and incidence of streptococcal bacteremia in patients submitted to hematopoietic stem cell transplantation. Patients were retrospectively evaluated and divided into group A (GA=38) and group B (GB=35). During hospitalization patients from GA performed oral hygiene daily with extra soft toothbrush and toothpaste besides performing mouth cleaning with an ethanol-free 0.12% chlorhexidine solution tree times a day. In contrast GB patients performed mouth cleaning with extra soft toothbrush and toothpaste, but no chlorhexidine was used. Usi…

AdultMaleToothbrushingbusiness.product_categoryAdolescentmedicine.medical_treatmentMouthwashesDentistryBacteremiaHematopoietic stem cell transplantationStreptococcus intermediusOral hygienelaw.inventionTooth brushingYoung AdultlawStreptococcal InfectionsmedicineMucositisHumansGeneral DentistryRetrospective StudiesToothpastebiologybusiness.industryIncidenceChlorhexidineChlorhexidineHematopoietic Stem Cell TransplantationMiddle Aged:CIENCIAS MÉDICAS [UNESCO]biology.organism_classificationmedicine.diseaseOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleToothbrushbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Efficacy of a Spray Compound Containing a Pool of Collagen Precursor Synthetic Amino Acids (L-Proline, L-Leucine, L-Lysine and Glycine) Combined with…

2010

Oral mucositis (OM) is a very frequent and potentially severe complication experienced by patients receiving chemotherapy and/or radiotherapy, which often leads to significant morbidity and mortality, and decreased quality of life, and is very costly. Despite its severity and prevalence, there is no standard recognised management today. The aim of this open clinical trial is to evaluate the efficacy and compliance of a new spray compound containing sodium hyaluronate (SH) and a pool of collagen precursor amino acids (AAs) combined with sodium hyaluronate (SH) to manage radio/chemotherapy-induced OM. Twenty-seven consecutive patients with OM were treated according to the manufacturer's inst…

AdultMalemedicine.medical_specialtyAdolescentProlineVisual analogue scalemedicine.medical_treatmentImmunologySodium hyaluronateGlycineAntineoplastic AgentsGastroenterologyLesionchemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologicheLeucineInternal medicinemedicineMucositisHumansImmunology and Allergyhyaluronic acid amino acids oral mucositis oral ulcer spray compound pain wound healingAmino AcidsHyaluronic AcidAdverse effectStomatitisAgedPain MeasurementAged 80 and overPharmacologyStomatitisChemotherapyRadiotherapybusiness.industryLysineMiddle Agedmedicine.diseaseSurgeryClinical trialchemistryHead and Neck NeoplasmsFemaleCollagenmedicine.symptombusinessInternational Journal of Immunopathology and Pharmacology
researchProduct

Prevalence of complications after the oral rehabilitation with implant-supported hybrid prostheses

2010

Objectives: Assess the main problems referred by the patients and observed by the professionals after the bucodental rehabilitation with an implant-supported hybrid prothesis. Patient and Methods: A retrospective study was carried out in which there were 43 patients included who were visited in the Department of Oral Surgery and Orofacial Implantology of University of Barcelona Dental School for one year. An oral rehabilitation with an implant-supported hybrid prosthesis was made to those patients. The following variables were registered: age, gender, number of inserted implants, type of implant and principal problems produced by the hybrid prosthesis. Results: The rehabilitation with an im…

AdultMalemedicine.medical_specialtyDental prosthesismedicine.medical_treatmentDentistryProsthesis DesignComplicacions quirúrgiquesProsthesisOral hygienePostoperative ComplicationsPrevalencemedicineMucositisHumansComplications of surgeryGeneral DentistryAgedRetrospective StudiesRehabilitationImplants dentalsbusiness.industryDental prosthesisDental implantsRetrospective cohort studyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseasePròtesis dentalsSurgeryProthesisOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleResearch-ArticleSurgeryDental Prosthesis Implant-SupportedImplantOral Surgerybusiness
researchProduct

A Narrative Review about Nutritional Management and Prevention of Oral Mucositis in Haematology and Oncology Cancer Patients Undergoing Antineoplasti…

2021

Cancer is a prevalent disease worldwide, and treatments such as radiotherapy and chemotherapy sometimes lead to adverse events. Oral mucositis is one of the most disabling adverse events, and clinical guidelines do not take into account nutritional interventions. The primary endpoint was to gather the evidence about the efficacy of nutritional interventions in the prevention and/or treatment of antineoplastic-induced oral mucositis in oncological patients. A bibliographic review was carried out in the PubMed data base by combining MeSH terms with Boolean operators. Articles were selected based on inclusion and exclusion criteria; 50 final articles were found. Although further evidence is ne…

AdultMalemedicine.medical_specialtyDiet therapyGlutaminemedicine.medical_treatmentAntineoplastic AgentsReviewDiseaseNeoplasmsmedicineMucositisClinical endpointHumanscancerTX341-641ChildAdverse effectIntensive care medicineStomatitisNutrition and DieteticsNutrition. Foods and food supplybusiness.industryCancerHoneyVitaminsmedicine.diseaseRadiation therapyTreatment Outcomediet therapyDietary SupplementsInclusion and exclusion criteriaFemalebusinessoral mucositisFood ScienceNutrients
researchProduct

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival…

2015

Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Methods Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only). We planned analyses of mature overall sur…

AdultMalemedicine.medical_specialtyGuanineLung NeoplasmsAfatinibPopulationMedizinPemetrexedNeutropeniaAdenocarcinomaAfatinibGastroenterologyDeoxycytidineGlutamatesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansRociletinibeducationLung cancerSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle Agedmedicine.diseasePrognosisGemcitabineSurgeryErbB ReceptorsSurvival RatePemetrexedOncologyMutationQuinazolinesFemaleCisplatinbusinessmedicine.drugFollow-Up StudiesThe Lancet. Oncology
researchProduct